Logo.png
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
April 19, 2024 16:30 ET | Hepion Pharmaceuticals, Inc.
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
Logo.png
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
March 06, 2024 08:30 ET | Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...
Logo.png
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
February 16, 2024 08:00 ET | Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...
Logo.png
Hepion Pharmaceuticals to Present at NASH-TAG 2024
January 03, 2024 17:15 ET | Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...